Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Propionic Acidemia Market Size Forecast: How Big Could The Market Get By 2030?
The market size for propionic acidemia has experienced consistent expansion in recent years. This market is projected to expand from $2.07 billion in 2025 to $2.15 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.1%. Historically, this growth has been driven by several factors, including advancements in newborn screening programs, heightened understanding of inherited metabolic disorders, the provision of supportive drug therapies, the proliferation of specialized metabolic clinics, and an increase in funding for rare disease research.
The propionic acidemia market is anticipated to experience consistent expansion in the coming years. This market is projected to achieve a value of $2.53 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 4.1%. This forecasted growth is largely driven by the escalating development of gene and enzyme therapies, augmented investments in orphan drug development, the broadening of precision medicine approaches, the increasing uptake of telemedicine for chronic care, and enhanced partnerships among research institutions. Key trends expected during this period include a heightened emphasis on early diagnosis and screening, a growing embrace of personalized treatment protocols, expanding investigations into rare metabolic disorders, the proliferation of specialized drug therapies, and improved patient oversight and administration.
Get A Free Sample Report With In-Depth Market Insights:
Propionic Acidemia Market Growth Drivers: What’s Behind The Acceleration?
A rising occurrence of genetic disorders is projected to fuel the expansion of the propionic acidemia market in the future. These disorders are conditions stemming from DNA mutations or abnormalities, which can be passed down hereditarily or arise without a clear cause, impacting health and developmental stages. The growing incidence of genetic disorders is linked to consanguineous marriages; such unions heighten the risk of inheriting recessive genetic mutations because identical defective genes can be transmitted from both parents, substantially increasing the probability of genetic conditions. Propionic acidemia contributes to better management of genetic disorders by providing specific treatments to correct metabolic imbalances, thereby enhancing patient results. As an illustration, in February 2024, the Osservatorio Malattie Rare (OMAR), a prominent independent journalistic agency located in Italy, reported that in 2023, Italian medical facilities identified 18 new disease-causing genes and monitored more than 18,000 patients suffering from rare diseases via regional networks. Consequently, the rising occurrence of genetic disorders is stimulating the expansion of the acidemia market.
Propionic Acidemia Market Segmentation: How Does The Market Break Down By Category?
The propionic acidemia market covered in this report is segmented –
1) By Drug Class: L-Carnitine, Antibiotics
2) By Route of Administration: Oral, Intravenous, Intramuscular
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By L-Carnitine Drug Class: Oral L-Carnitine, Injectable L-Carnitine
2) By Antibiotic Drug Class: Oral Antibiotics, Injectable Antibiotics
Propionic Acidemia Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies in the propionic acidemia market are prioritizing the development of innovative mRNA-based treatments to tackle the core genetic issues causing the disease. mRNA therapies represent a form of medical intervention that employs messenger RNA to instruct cells to generate proteins capable of preventing or treating conditions by targeting their genetic foundations. For example, in May 2023, Moderna, a US-based pharmaceutical and biotechnology company, disclosed interim results from the Phase 1/2 trial of mRNA-3927, an investigational mRNA therapy for propionic acidemia. This therapy leverages mRNA to deliver functional copies of the PCCA and PCCB genes, aiming to restore enzyme activity in the liver and potentially decrease metabolic decompensations. This pioneering treatment strategy is intended to enhance patient outcomes by addressing the genetic root cause of the disease, offering fresh hope to individuals suffering from this uncommon metabolic disorder.
Propionic Acidemia Market Competitive Overview And Top Companies
Major companies operating in the propionic acidemia market report are Recordati Rare Diseases Inc, Horizon Therapeutics plc, Travere Therapeutics (Retrophin Inc), Mitsubishi Tanabe Pharma Corporation, Ultragenyx Pharmaceutical Inc, Moderna Inc, Krystal Biotech Inc, Astellas Pharma Inc, Synlogic Inc, Encoded Therapeutics Inc, BridgeBio Pharma Inc, VectivBio AG, Agios Pharmaceuticals Inc, CoA Therapeutics Inc, Imbria Pharmaceuticals Inc, Comet Therapeutics Inc, Swedish Orphan Biovitrum AB (Sobi), Regenacy Pharmaceuticals, Audentes Therapeutics, Vertex Pharmaceuticals.
View The Full Propionic Acidemia Market Report:
Propionic Acidemia Market Regional Breakdown: Where Is Demand Concentrated?
North America was the largest region in the propionic acidemia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the propionic acidemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.